Abstract Tumor necrosis factor alpha
Introduction
Tumor necrosis factor alpha (TNF ) has broad eVects in the immune system including lymphoid organ development as well as the growth, survival und function of immune cells [1] . Two main functions of TNF , regulatory eVects and proinXammatory activities, are known. The pathogenesis of several autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis (JIA), psoriatic arthritis and Crohn's disease (CD) has been linked to an elevated TNF expression at the site of inXammation [2] . However, due to the complex function of TNF , immunodysregulation and even proinXammation have been reported. Patients treated with TNF antagonists can develop several diseases including autoimmune or autoinXammatory conditions like systemic lupus erythematodes, uveitis, encephalomyelitis, glomerulonephritis, sarcoidosis, other granulomatous lesions and chronic inXammatory bowel disease [3, 4] . Thus, TNF blockade has to be monitored in this regard.
We report on an 11-year-old girl with JIA, who developed CD while taking etanercept for her arthritis. Etanercept is a fusion protein consisting of the extracellular portion of the human TNF receptor linked to the Fc portion of human IgG. In particular, etanercept treatment has been associated with the induction of CD in adults and occasionally also in children and adolescents [3, 4] .
Case report
A Caucasian 11-year-old, otherwise healthy girl had developed rheumatoid factor negative JIA at the age of 7 years. The family history was not indicative of any autoimmune diseases or intestinal disorders. At the time of JIA diagnosis, antinuclear antibodies were positive (titer 1:320) and rheumatoid factors (IgM, IgA and IgG) were negative. Arthritis involved the elbows, hands, Wngers, both ankles and some toes. There was no ophthalmologic involvement, especially no iridocyclitis. Treatment with non-steroidal anti-inXammatory drugs, glucocorticoids and methotrexate (MTX) was started eVectively; however, the patient did not reach complete remission. After 3 years, the patient developed MTX-related side eVects including vomiting and abdominal pain and refused to take MTX. Therefore, medication was changed to TNF blockade using etanercept (weekly subcutaneous dose of 0.8 mg/kg). A complete remission of JIA was achieved. Thus, glucocorticoid treatment was reduced from 245 mg prednisone/week (1.1 mg/ kg per day) to 2.5 mg/week. NSAID medication (naproxen) was discontinued.
However, 1 year after etanercept therapy had been started, the patient developed intestinal symptoms with massive bloody diarrhea and abdominal pain. No infectious agents were detected. Chronic intestinal inXammatory disease was suspected and an endoscopy was performed. The colonoscopy showed ulceration and mucosal swelling of the terminal ileum, cecum and proximal colon. No stenosis was seen. A gastroduodenoscopy was normal. The diagnosis of CD was conWrmed by histology. Epitheloid granulomas were present. At that time, autoantibody titers were repeated and a change in the proWle was found. ANA were now negative (<1:80), whereas, c-and x-ANCA were positive (titer 1:5,120) and rheumatoid factors remained negative. Furthermore, we determined the HLA-B27 status, which was negative. NOD 2/CARD15 (nucleotide oligomerization domain; caspase activation and recruitment domain) gene single nucleotide variants were examined and a single heterozygous R702W (exon 4) mutation was found.
Since intestinal problems started during etanercept therapy, we decided to discontinue this drug and to start a therapy with sulfasalazine (50 mg/kg per day) as well as a nutritional therapy (modulen ® diet; Nestle Inc., Lausanne, Switzerland). Unfortunately, bowel symptoms did not improve signiWcantly and she newly developed ankle pain and arthritis. We decided to again start a TNFblocking medication targeting both the joint and gastrointestinal symptoms. Antibody-based TNF-blocking medications have not been associated with the induction of chronic inXammatory bowel disease. Thus, we decided to introduce adalimumab. Of note, since the girl had not tolerated MTX comedication in the past, inXiximab was not considered as an alternative, since MTX comedication is necessary to reduce induction of anti-inXiximab antibodies. Under adalimumab therapy, a clinical remission of intestinal and articular disease was achieved rapidly and consistently. After 9 months, the patient is still in remission.
Discussion
We report the case of an 11-year-old girl who developed CD during etanercept therapy for JIA. There are only a few reports on the development of chronic inXammatory intestinal diseases associated with etanercept therapy. Most of the described patients were diagnosed with ankylosing spondylitis or psoriatic arthritis [2, 5, 6] . These patients are known to have a higher risk for developing chronic inXammatory bowel disease, whereas patients with JIA are not predisposed to developing CD, except adolescents aVected by enthesitis-related arthritis or psoriatic arthritis. In these latter groups of patients, it would be diYcult to evaluate whether CD was a side eVect or coincidentally appearing.
There are several large follow-up studies on the safety and eVectiveness of etanercept in JIA, which could show that a signiWcant proportion of patients had improved joint aVection during therapy [3, 4, 7] . Serious adverse events including gastrointestinal disease, sarcoidosis, sepsis, tuberculosis and malignancy were low (incidence of severe adverse events being 0.029 per patient year in total) [3, 4, 7] .
There is one report of a boy with oligoarticular, ANA-positive, rheumatoid factor negative JIA and CD [8] . However, this patient had already developed intestinal symptoms before etanercept therapy and symptoms aggravated during etanercept. The patient went into remission of JIA and CD with inXiximab treatment. Our patient had been free of symptoms, inconsistent with CD before and during the Wrst year of etanercept treatment.
Etanercept, inXiximab and adalimumab appear to be comparably eVective in treating signs and symptoms attributed to musculoskeletal inXammation including arthritis, tendinitis, sacroiliitis and spondylitis [3, 4, 7] . However, with respect to inXammation of the gut, the anti-TNF antibodies inXiximab and adalimumab have been eVective in controlling disease, whereas etanercept has shown to be ineVective [9] . The diVerent binding patterns of TNF and the biological action related to the antibody structure may explain the distinct biological eVects of these anti-TNF drugs. A further hypothesis is that that neutralization of soluble TNF by etanercept may result in a counter-regulatory increase of cytokines, partly because T cells themselves remain "unaVected" by etanercept [3, 4, 7] . Increased counter-regulatory production of cytokines on etanercept therapy may contribute to the onset of CD [5, 6] . Furthermore, studies demonstrate that monoclonal anti-TNF antibodies induced apoptosis of activated peripheral blood lymphocytes and lamina propria T cells by directly binding to their surface [10, 11] .
SWkakis et al. suggested that under certain circumstances, TNF -blocking agents may promote the activation of autoreactive T cells, leading to tissue damage via auto-immune eVector mechanisms. This scenario can lead to the induction of ANA antibodies and an SLE-like syndrome, predominantly observed with inXiximab and the occurrence of other inXammatory diseases including uveitis, CD and cerebral demyelination particularly during therapy with etanercept [12] [13] [14] . Of interest, we found a change in the autoantibody proWle of our patient after 1 year of etanercept therapy. We could not Wnd a comparable case with a documented induction of c-/x-ANCA-autoantibodies; however, the induction of anti-double-stranded DNA antibodies has been described [15, 16] .
It is documented that blockade of TNF by etanercept can enhance T cell production of IFN gamma (IFNg) and TNF [2, 6] . It is known that in genetically susceptible individuals, increased levels of IFNg and TNF in the intestinal mucosa can trigger inXammatory bowel disease [17] . Individuals with recently described NOD2/CARD15 gene variants may be at risk for this side eVect [17] . A similar eVect on the cytokine production of T cells present in the central nervous system may explain the increased frequency of inXammatory neurological complications [14, 18] . In this regard, we looked at NOD2/CARD15 gene variants in our patient and found a mutation at R702W. This mutation was found in approximately 4-5% of the healthy population and in over 10% of patients with particular autoimmune diseases, especially in CD [17, 19] . Whether this mutation is disease relevant in our patient is unclear, but it might be a predisposition for CD. We did not analyze mucosal T cell activation in our patient during etanercept therapy, but TNF production in the sera of this patient was tested. We found elevated TNF ELISA values before and during treatment with etanercept (TNF in serum at diagnosis of polyarthritis 99.8 pg/ml (normal below 8.1 pg/ml serum), after 3 months of etanercept treatment at 152 pg/ml). At diagnosis of CD, TNF levels increased to 418 pg/ml. In the future, it would be interesting to analyze mucosal TNF production.
Since TNF is believed to play a key role in the pathogenesis of CD [20] and TNF antibodies have been used successfully for management of pediatric CD [8] [9] [10] , 21], we therefore decided to switch therapy. There were two possibilities: inXiximab or adalimumab.
Because of former MTX intolerance in our patient, adalimumab was preferred [22] . In contrast to inXiximab, adalimumab contains only human amino acid sequences. Thus, it is thought to be less immunogenic than inXiximab [23] . Until now, only limited experience exists with respect to adalimumab treatment in childhood. There is a study on 14 children with CD treated with adalimumab: 50% of these patients showed complete remission after a mean of Wve injections and 36% did not improve. The most frequent side eVects were nausea and vomiting. No severe side eVects were described [23] .
Lovell et al. [24] presented the 2-year safety and eYcacy data of adalimumab treatment of juvenile rheumatoid arthritis in 171 patients. Serious side eVects included neutropenia, herpes virus infection and pneumonia. No malignancies, tuberculosis or death occurred. However, recent studies showed an increased risk of lymphoma in adults taking adalimumab, particularly in conjunction with azathioprine [25] .
Until the present time, our patient showed no side eVect and had stable clinical remission of both gut and joint disease after 9 months of therapy.
